Use your browser's back button to choose another title or click here for a New Search.

How to Get the Presentation

 Download PDF (free)



Bookmark and Share



A Multi-Site, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence.

Presented at the College on Problems of Drug Dependence (CPDD) annual meeting, San Juan, Puerto Rico, June 14-19, 2014.

Theresa M. Winhusen, PhD (University of Cincinnati, OV Node).

This presentation reports on a National Drug Abuse Treatment Clinical Trials Network (CTN) study that aimed to evaluate the potential efficacy of buspirone as a relapse-prevention treatment for cocaine dependence (CTN-0052). This randomized, double-blind, placebo-controlled, 16-week pilot trials was conducted at 6 clinical sites. Adults meeting DSM-IV-TR criteria for current cocaine dependence scheduled to be in inpatient/residential substance use disorder (SUD) treatment for 12-19 days when randomized, and planning to enroll in local outpatient treatment through the end of the active treatment phase, were randomized to buspirone titrated to 60 mg/day (n=35) or to placebo (n=27). All participants received psychosocial treatment as usually provided by the SUD treatment programs in which they were enrolled. Outcome measures included maximum days of continuous cocaine abstinence (primary), proportion of cocaine use days, and days-to-first-cocaine-use during the outpatient treatment phase (study weeks 4-15) as assessed by self-report and urine drug screens.

Study retention was high, with a 94% completion rate, and medication adherence was also strong (85% based on medication events monitoring system). However, there were no significant treatment effects on maximum continuous days of cocaine abstinence or days to first cocaine use. Additionally, buspirone, relative to placebo, actually increased the proportion of cocaine use days in female participants, though not in males.

Conclusions: These results suggest that buspirone is unlikely to have a beneficial effect on preventing relapse to cocaine use and may even worsen cocaine use outcomes for women. (Presentation, PDF, English, 2014)

Keywords: Buspirone | Cocaine | Crack cocaine | Gender differences | Pharmacological therapy | Relapse prevention | Women | College on Problems of Drug Dependence (CPDD) annual meeting, 2014

Document No: 1084.

Submitted by Theresa Winhusen, PhD, OV Node, 7/30/2014.

Winhusen, Theresa M. mail
NIDA-CTN-0052 www
Ohio Valley (Lead) www
Appalachian Tri-State www
Delaware Valley www
Florida Node Alliance www
Southern Consortium www
Texas www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 7/2014 --